SAA-domain-specific antibodies and peptide antagonists and use thereof to treat inflammatory diseases
Isolated SAA peptides, fusion proteins and compositions comprising such are provided as are domain-specific SAA antibodies. Methods of treating sepsis and endotoxemia are also provided.
1. A fusion protein comprising an immunoglobulin fragment crystallizable region (Fc) and a peptide consisting of SEQ ID NO:8 or SEQ ID NO:9, wherein the fusion protein does not comprise SEQ ID NO:10, 11 or 12.
2. The fusion protein of claim 1 , wherein the peptide comprises SEQ ID NO:9.
3. The fusion protein of claim 1 , wherein all amino acid residues of the peptide are D-amino acids.
4. The fusion protein of claim 1 , wherein all amino add residues of the peptide are L-amino acids.
5. The fusion protein of claim 1 , wherein the composition comprises a carrier.
6. The fusion protein of claim 5 , wherein the carrier is a pharmaceutically acceptable carrier.
7. The fusion protein of claim 1 , wherein the fusion protein comprises the isolated peptide bonded via a peptide bond at an N-terminal thereof or a C-terminal thereof to a second peptide, polypeptide or protein.
8. The fusion protein of claim 1 , wherein the peptide is bonded via a peptide bond at an N-terminal thereof or a C-terminal thereof to the Fc.
9. The fusion protein of claim 8 , wherein the Fe has a sequence identical to a human Fc.